Weymouth and Portland Locality DVT Pathway for NOAC

Appendix 1

Refer to further information e.g. NOAC contraindications, dose reductions in:

- > The summary of product characteristics (spc) for the relevant NOAC available at http://www.medicines.org.uk/emc/
- > Dorset CCG Shared Care guidelines for Rivaroxaban for treatment of DVT and PE
- > NICE TA261 Rivaroxaban for the treatment of DVT and prevention of recurrent DVT and PE (2012)

